Antiviral activity and safety of LB80380 in hepatitis B e antigen–positive chronic hepatitis B patients with lamivudine‐resistant disease
Man‐Fung Yuen, Kwang‐Hyub Han, Soon‐Ho Um, Seung Kew Yoon, Hye‐Ryon Kim, John Kim, Chung Ryeol Kim, Ching‐Lung Lai – 30 November 2009 – We aimed to determine the antiviral activity and safety of a new nucleotide analogue, LB80380, in chronic hepatitis B (CHB) patients with lamivudine‐resistant virus. Sixty‐five patients with lamivudine‐resistant virus were randomized to receive five ascending daily doses (30, 60, 90, 150, 240 mg) of LB80380. LB80380 was given together with lamivudine for the first 4 weeks, followed by 8 weeks of LB80380 monotherapy.